



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/036,111	11/09/2001	Stefan Peters	1/1166

CONFIRMATION NO. 8220

28501


BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P. O. BOX 368
RIDGEFIELD, CT 06877

FORMALITIES LETTER



OC000000008261186

Date Mailed: 06/10/2002



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Peters, S. et al) Art Unit: 1614
Serial No. : 10/036,111) Examiner: To be assigned
Confirmation No. : 8220
Filed : November 9, 2001
For : FAP-activated anti-tumor compounds
Docket No. : 1/1166

TECH CENTER 1600/2900

AUG 0 9 2002

RECEIVED

#9

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 CFR § 1.821(f)

Sir:

I hereby certify that:

The paper sequence and computer readable sequence listing submitted herewith
are identical.

Respectfully submitted,

David Dow
Reg, 46,124

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 791-6214
Docket No.: 1/1166

I hereby certify that this correspondence is
being deposited with the U.S. Postal Service
as First Class Mail in an envelope addressed
to:

Box Missing Parts
Assistant Commissioner for Patents
Washington, DC 20231

on August 1, 2002

By: David Dow
Reg. No. 46,124



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614
RECEIVED
AUG 09 2002
TECH CENTER 1600/2900

Application of : Peters, S. et al) Art Unit: 1614
Serial No. : 10/036,111) Examiner:
Confirmation No. : 8220
Filed : November 9, 2001
For : FAP-activated anti-tumor compounds
Docket No. : 1/1166

TRANSMITTAL LETTER

United States Patent and Trademark Office
ATTENTION: BOX SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In complete response to the Office communication concerning the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures dated June 10, 2002, enclosed please find:

[X] A copy of the "Sequence Listing" in computer readable form in compliance with 37 C.F.R. §§1.823(b) and 1.824.

[X] A statement that the content of the paper and computer readable copies are the same as set forth in 37 C.F.R. §1.821(f).

The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment to Deposit Account No. 02.2955. A duplicate copy of this paper is enclosed.

Respectfully submitted,

David A. Dow
Attorney for Applicant(s)
Reg. No. 46,124

Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 791-6214
Date: August 1, 2002